Merck & Co.
AWARDS
NEWS
In April, Dr. Robert Redfield, the new head of the CDC, boldly predicted that the AIDS epidemic can be defeated by 2025. This morning Merck, Janssen and Gilead all released clinical data for HIV treatments that could make Redfield’s prediction a reality.
Yesterday, top-line data from Bionomics Limited revealed details of the biopharmaceutical company’s Phase II clinical trial of BNC210 in regards to patients with post traumatic stress disorder.
Janssen Biotech, a Johnson & Johnson company, informed Aduro Biotech that it was terminating its research and license deals related to Aduro’s Listeria treatment for cancers.
Harnessing the body’s own immune system to fight cancer has been one of the key focuses of drugmakers over the past several years. This year, the Nobel committee recognized two research pioneers for their trailblazing efforts in this field.
Pfizer announced its succession plan for when Ian Read steps down as chief executive officer on January 1, 2019. The new chief executive officer will be Albert Bourla, who is currently the company’s chief operating officer.
Dragonfly Therapeutics struck a licensing agreement worth up to $695 million with Merck. Merck will license exclusive rights to Dragonfly’s TriNKET technology platform for a number of solid-tumor programs, the company announced today.
JOBS
IN THE PRESS